🌱Synthesized Clinical Bottom Line updated 11-15-2025 The provided body of evidence, including two meta-analyses and several large prospective cohort studies, indicates that post-diagnosis soy food consumption is safe and likely beneficial for breast cancer survivors. Contrary to long-standing concerns fueled by inapplicable mouse models, the human data consistently show that moderate soy intake is associated […]
Comment: This small but powerful study on dietary flaxseed is a great reminder that simple, well-tolerated dietary interventions can have profound biological effects in breast cancer. It also helps address a persistent misinterpretation, which is that flax can act negatively in breast cancer patients. The study shows a significant reduction in the Ki-67 index (cell […]
Comment: This large pooled analysis gives us several interesting and important pieces of information. Although this study was with breast cancer patients, there is no reason to believe it doesn’t apply to every cancer. The magnitude of risk associated with common, non-oncology drugs is genuinely alarming. PPI use, a near-universal practice for GI prophylaxis and […]
Comment: Metronomic chemotherapy (mCHT) is a concept that’s been around, but it’s often overlooked in favor of high-dose regimens. This 2022 review from J. Clin. Med. brilliantly frames the evidence, separating the clear “lights”—like its low-toxicity profile—from the persistent “shadows” we still face, such as the lack of large randomized trials. For our frail or […]
Comment: The MECCA trial, while certainly not practice-changing, provides an important signal for the potential of metronomic chemotherapy. The key takeaway is the therapeutic window. Achieving a 9-month PFS benefit and a positive OS trend with a regimen that produced Grade 3 adverse events in only 15.1% of patients is compelling. This highlights the central […]
Comment: This study presents a very practical and appealing option for managing advanced HER2-negative breast cancer in the palliative setting. The key takeaway is the dual advantage of this all-oral metronomic regimen: it demonstrates clinically relevant activity while maintaining an exceptionally low toxicity profile. However, the regimen’s main strength is its safety and convenience. Being […]
Comment: This is an interesting and potentially alarming one. I’m sure we’ve all noted times where a stable patient started progressing after getting an infection. This study shows an association of SARS-CoV-2 infection with a nearly two-fold increase in cancer-specific mortality (UK Biobank) and a 44% higher rate of lung metastases in breast cancer patients […]
Comment: This meta-analysis is a classic example of how pooling heterogeneous and methodologically different studies can create confusion. In general I am always suspicious of meta-analyses for that reason. Although it is possible that there is a biological reason for the studies on Asian women to be different than on Western, it is also possible […]
Comment: For years, people have been inappropriately scared of soy both in terms of causing breast cancer and negatively impacting progression once they have it. There is a group of people out there who are continuing to promote that despite all evidence to the contrary. The key finding of this study is not just that […]
Comment: A common question from breast cancer survivors is whether soy is safe to eat. This post breaks down a 2012 Chinese study that explored this topic. The researchers found a positive association between high soy intake and improved survival for breast cancer patients, particularly those with ER-positive tumors. Summary: Clinical Bottom Line This prospective […]
